

Histomorphometric Analysis of the Alveolar Bone for Two Weeks after Bone Morphogenetic Protein Transfer

Mariko Kawai* and Kiyoshi Ohura

Department of Pharmacology, Osaka Dental University, Osaka, Japan

Abstract

Alveolar bone regeneration therapy is critical to retain the teeth and proper occlusion. Currently, alveolar bone loss is treated surgically using bone grafts or artificial bone, both of which carry the risk of complications, such as post-operative infection. A new, non-surgical therapy would help to improve patient safety levels and treatment success. Alveolar bone is always proceeding remodelling, and this makes it difficult for the clinicians and researchers to evaluate alveolar bone tissues after some regenerative treatments. In our previous studies, we developed a system for bone regeneration using non-viral bone morphogenetic protein (BMP) gene-expression plasmid vectors and *in vivo* electroporation for the ectopic bone formation in rat skeletal muscles. Here, we used bone morphometric analyses using calcein and tetracycline labelling in rats to evaluate changes in alveolar bone with our BMP gene-transfer system. We concluded that BMP-2/7 gene transfer to the periodontal tissues was an optimal therapy for the alveolar bone regeneration.

Keywords: Alveolar bone; Histomorphometric analysis; Bone labelling; Gene therapy

Introduction

Alveolar bone is pivotal for the maintenance of teeth [1]. However, when lost, alveolar bone has limited potential for spontaneous regeneration [2]. Therefore, numerous studies have investigated ways to successfully engineer new bone that is efficient and safe for clinical therapy [3]. However, because alveolar bone is in a constant state of remodeling-more so than most other bony regions-it can be difficult to evaluate whether a method has been successful in regenerating bone at the intended site [4-6]. Moreover, bone and teeth are generally more difficult to handle than other types of tissues, requiring lengthy decalcification procedures before the specimens can be assessed [7].

Previously, we developed a gene-transfer system for bone regeneration therapy by combination a non-viral BMP gene expression plasmid vector and *in vivo* electroporation [8,9]. Our final goal is to apply our constructed method clinically for alveolar bone regeneration [10] and to limit new bone formation to the appropriate site. Our previous study revealed that the observation for one week after BMP gene transfer to the periodontal tissues was not enough to evaluate the regenerated alveolar bone [11]. To resolve this problem, we require a suitable and reliable evaluation method to detect regenerated alveolar bone after gene therapy for continuous period of time. Here, we used a histomorphometric analysis to value alveolar bone regeneration for two weeks after BMP-2/7 gene transfer.

Aim

Aim of this study is to reveal the availability for histomorphometric analyses on the alveolar bone for two weeks after BMP gene transfer.

Materials and Methods

Gene transfer

Nine-week-old male Wistar rats ($n=3$) were anesthetized via an intraperitoneal injection of pentobarbital sodium (5.0 mg/100 g body weight). The BMP-2/7 gene expression plasmid vector detailed in our previous study (9) was diluted to 0.5 $\mu\text{g}/\mu\text{L}$ in phosphate-buffered saline and 50 μL was injected into the palatal region of the periodontal tissues of the first molar in the right maxilla using a syringe with a 31-gauge

needle. *In vivo* electroporation was performed immediately in the condition of 50 V, 50 ms and 32 pulses [12]. All animal experimental procedures were approved by the Animal Care and Use Committee, Okayama University (Approval number: oku-2012137) and Animal Research Committee of Osaka Dental University (Approval number: 16-1009).

Double-staining of bone

Nine-week-old male Wistar rats ($n=3$) were intraperitoneally injected with calcein (10 mg/kg) on the day of gene transfer. Three days later, tetracycline hydrochloride (30 mg/kg) was intraperitoneally injected. Rats were again injected with calcein on days 6 and 12, and tetracycline on day 9, and then sacrificed with an overdose of pentobarbital sodium on day 14 (Figure 1). The maxillary regions of rats were dissected and fixed with 70% ethanol for 8 days, stained with Villanueva osteochrome bone stain for 10 days, dehydrated with increasing concentrations of ethanol, and embedded in methyl methacrylate without decalcification [13].

After polymerization, 10- μm frontal sections were obtained from the mesiolingual center of the upper first and second molars the region of alveolar bone surrounding the second molar was used as an untreated control for the experiment. In addition, a site of alveolar bone around the first molar away from the site of injection was also used as a control, as was the same site in the second molar. Sections were observed by fluorescence microscopy under UV irradiation for tetracycline (364 nm) and calcein (477 nm) labeling. The distances between the calcein and tetracycline labels were measured vertically at 10 points within the

*Corresponding author: Kawai M, Department of Pharmacology, Osaka Dental University, 8-1 Kuzuhahanazono-cho, Hirakata-City, Osaka, 573-1121, Japan, Tel: +81-72-864-3058; Fax: +81-72-864-3158; E-mail: kawai-m@cc.osaka-dent.ac.jp

Received November 01, 2017; Accepted November 20, 2017; Published November 30, 2017

Citation: Kawai M, Ohura K (2017) Histomorphometric Analysis of the Alveolar Bone for Two Weeks after Bone Morphogenetic Protein Transfer. J Cytol Histol 8: 486. doi: [10.4172/2157-7099.1000486](https://doi.org/10.4172/2157-7099.1000486)



Copyright: © 2017 Kawai M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

region in which gene transfer had been performed, using a Histometry RT Camera (System Supply, Tokyo, Japan). Statistical analyses was performed by analysis of variance (ANOVA), following by Fisher's comparison test.

Results



Villanueva bone staining

Villanueva osteochrome bone staining was used to measure alveolar bone changes following gene transfer into the region of the first molar, comparing against the region around the second molar as an untreated control. With this staining, osteoid is transparent green to jade green or homogeneous red low-density bone is red, the nuclei of osteoblasts or osteocytes are greenish-blue to dark purple, and the cellular cytoplasm green or light green represented the cytoplasm. After *BMP-2/7* gene transfer, we found no significant differences in osteoid or low-density bone formation between the alveolar bones of the first molars and second molars (Figure 2A and 2B). However, in comparing the morphology of the osteoblasts, numerous osteoblasts in the alveolar bone around the first molars were cuboidal in shape (Figure 2A arrow), typical of active osteoblasts. In contrast, osteoblasts in the alveolar bone of the second molar were squamous-like, reminiscent of lining cells (Figure 2B, arrow).



Bone labeling and MAR

We found five labels in the alveolar bones of the first molars and second molars (Figures 3A and 3B). We measured the distances between each label (Mineral Apposition Rate: MAR) and compared them between the alveolar bones of the first molars and second molars. The MAR values for the first molar with *BMP-2/7* from 0–3 days, 3–6 days, 6–9 days and 9–12 days after gene transfer were significantly different to those for the second molar (Figure 4A). In comparison, the MAR for the uninjected control sites of both the first and second molars was not significantly different (Figure 4B).



Discussion

We transferred a *BMP-2/7* non-viral vector into the periodontal tissues of the first molars of rats with electroporation, and found that *BMP-2/7* gene transfer can increase the MAR of alveolar bone. Moreover, the influence of *BMP-2/7* gene transfer was limited to the targeted region of alveolar bone, without affecting adjacent alveolar bone of the second molar. In the past, gene therapy has been used to target a general change rather than a local change [14-16]. However, in alveolar tissues, it is very important that *BMP-2/7* gene transfer targets only the intended periodontal tissues and not the surrounding regions, which lie adjacent to the site of interest.

Preparing bone samples for histological analysis can require an extensive processing time because of the need to decalcify the samples [17]. Moreover, histological staining of sections with hematoxylin and eosin demonstrates only a snapshot or the fragmental changes in bone tissue growth. Histomorphometric analyses with the use of dyes can reveal the time-dependent changes in bone formation [18]. This is an important distinction, as alveolar bone is always remodeling and changing [19]. Therefore, histomorphometric analyses offer a suitable way to evaluate potential alveolar bone regeneration [20].

In our previous study, although we found the inflammatory cells until three days in the target site, new bone like tissues were formed on day five after *BMP-2/7* gene transfer [11]. Our final goal is to apply our alveolar bone regeneration system for the patients are under the control of the periodontitis.

Conclusion

Our histomorphometric analyses revealed that *BMP-2/7* gene transfer by *in vivo* electroporation could increase the potential for alveolar bone regeneration at specific periodontal tissues sites. This method may represent a new clinical therapy for alveolar bone regeneration.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Basic Research B Number 24300182) and the Daiwa Health Sciences Foundation.

References

1. Intini G, Katsuragi Y, Kirkwiid KL, Yang S (2014) Alveolar bone loss: mechanisms, potential therapeutic targets, and interventions. *Adv Dent Res* 26: 38-46.
2. Du J, Li M (2017) Functions of periostin in dental tissues and its role in periodontal tissue's regeneration. *Cell Mol Life Sci* 74: 4279-4286.
3. Mardas N, Dereka X, Donos N, Dard M (2014) Experimental model for bone regeneration in oral and cranio-maxillo-facial surgery. *J Invest Surg* 27: 32-49.
4. Peric M, Dumic-Cule L, Grcevic D (2015) The rational use of animal models in the evaluation of nobel bone regenerative therapies. *Bone* 70: 73-86.
5. Li Z, Müller R, Ruffoni D (2017) Bone remodeling and mechanobiology around implants: Insights from small animal imaging. *J Orthop Res Oct* 3.
6. Husain A, Jeffries MA (2017) Epigenetics and bone remodelling. *Curr Osteoporos Rep* 15: 450-458.
7. Mashiba T (2011) Morphological analysis of bone dynamics and metabolic bone disease. Histological findings in animal fracture model-effects of osteoporosis treatment drugs on fracture healing process. *Clin Calcium* 21: 551-558.
8. Kawai M, Bessho K, Kaihara S, Sonobe J, Oda K, et al. (2003) Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. *Hum Gene Ther* 14: 1547-1556.
9. Kawai M, Maruyama H, Bessho K, Yamamoto H, Miyazaki J, et al. (2009) Simple strategy for bone regeneration with a *BMP-2/7* gene expression cassette vector. *Biochem Biophys Res Commun* 390: 1012-1017.
10. Kawai M, Ohura K (2016) Gene therapy using non-viral gene expression vector and *in vivo* electroporation for bone regeneration: Challenge to gene transfer into the periodontal tissues. *J Biomed Engeer Biosci* 3: 18-21.
11. Kawai M, Kataoka Y, Sonobe J, Yamamoto H, Inubushi M, et al. (2017) Non-surgical model for alveolar bone regeneration by bone morphogenetic protein-2/7 gene therapy. *J Periodontol* 18: 1-18.
12. Yamamoto H, Kawai M, Shiotsu N, Watanabe M, Yoshida Y, et al. (2012) *BMP-2* gene transfer under various conditions with *in vivo* electroporation and bone induction. *Asian J Oral Maxillo Surg*. 24: 49-53.
13. Kawai M, Ohura K (2017) Applicability of histomorphometry analysis for evaluating alveolar bone regeneration after gene transfer. *J Histol Histopathol Res* 1: 21-22.
14. Dobayashi M, Goda K, Maruyama H, Fujisawa M (2005) Erythropoietin gene transfer into rat testes by *in vivo* electroporation may reduce the risk of germ cell loss caused by cryptorchidism. *Asian J Androl*. 7: 369-373.
15. Abe S, Hanawa H, Hayashi M, Yoshida T, Komura S, et al. (2005) Prevention of experimental autoimmune myocarditis by hydrodynamics-based naked plasmid DNA encoding CTLA4-Ig gene delivery. *J Card Fail* 11: 557-564.
16. Ataka K, Maruyama H, Neichi T, Miyazaki J, Gejyo F (2003) Effects of erythropoietin -gene electrotransfer in rats with adenine-induced renal failure. *Am J Nephrol* 23: 315-323.
17. Endo N, Yamamoto T, Seki A, Ozawa E, Sano H (2014) Modern bone histomorphometry. *Niigata: We Net Company* 5: 8-77.
18. Yamamoto, Shimakura T, Takahashi H (2015) Bone cell biology assessment by microscopic approach. *Bone histomorphometry of remodeling, modelling and minimodeling*. *Clin Calcium* 25: 1491-1497.
19. Xiao W, Wang Y, Pacios S, Li S, Graves DT (2016) Cellular and molecular aspects of bone remodeling. *Front Oral Biol* 18: 9-16.